|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Frontline therapy** | **Outcome** | **Second line therapy** | **Outcome** | **Third line therapy** | **Outcome** |
| Active surveillance (AS)*N = 38**\*1 outcome missing* | Spontaneous regression | *9**(24%)* |  |
|  |  | None | *11* |  |  |  |
| Stable disease  | *16**(43%)* | Surgery | *2* | No recurrence | *2* |
| Celecoxib | *1* | Regression | *1* |
| Sorafenib | *1* | Regression | *1* |
| Meloxicam | *1* | Regression | *1* |
| Progression | *12**(33%)* | AS | *2* | Stable disease | *2* |  |  |
| Surgery | *5* | No recurrence | *5* |
| HIFUa | *1* | Progression | *1* |
| Meloxicam | *1* | Stable disease | *1* |
| Vinorelbine | *3* | Stable disease | *1* |
| Regression | *1* |
| Progression | *1* | Sorafenib | *1* | Regression | *1* |
| Surgery*N = 23**\*1 outcome missing* | No recurrence | *16**(73%)* |  |  |  |  |
| Recurrence | *5**(23%)* | AS | *4* | Stable disease | *4* |  |
| Vinorelbine | *1* | Stable disease | *1* |  |
| Residual disease (R2) | *1**(4%)* | AS | *1* | Stable disease | *1* |  |
|  Celecoxib*N = 1* | Stable disease | *1* |  |  |  |  |

Figure 1 – Treatment and treatment outcomes

a) HIFU: High Intensity Focused Ultrasound.